Vedanta's CDI product VE303 well tolerated in Phase I

Vedanta Biosciences Inc. (Cambridge, Mass.) said single and multiple ascending doses of VE303 given following vancomycin were well tolerated in 23 healthy adult volunteers in an open-label Phase Ia/Ib trial. The company plans to start a Phase II trial this quarter of VE303 to treat recurrent Clostridium difficile infection (CDI). VE303 is an orally delivered powdered consortium of live human microbiome-associated bacterial strains.

Vedanta also said VE303 treatment led to rapid, dose-dependent colonization of VE303 strains that lasted for at least 12 weeks, and accelerated gut microbiota restoration after antibiotics...